Success of prolonged therapy with the somatostatin analog, octreotide acetate, in recalcitrant enterocutaneous fistulas

Mark Tulchinsky, Barbara L. Bass, Martin J. Collen, John W. Harmon, Kenneth L. Becker

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The somatostatin analog, octreotide acetate, has been reported to accelerate closure of enterocutaneous fistulas (ECF), and, if the closure does occur, it does so within 10 days of therapy. We report on the closure in 2 consecutive patients with recalcitrant, high output ECF after 4 and 6 weeks of octreotide acetate therapy. The changes in fistula output volume and content in response to the drug are described. Since long-term treatment with this drug is generally well tolerated and easy to administer, at least a 6-week course should be considered before resorting lo surgical resection.

Original languageEnglish (US)
Pages (from-to)142-145
Number of pages4
JournalDigestive Surgery
Volume6
Issue number3
DOIs
StatePublished - Jan 1 1989

Fingerprint

Intestinal Fistula
Octreotide
Somatostatin
Pharmaceutical Preparations
Fistula
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Gastroenterology

Cite this

Tulchinsky, Mark ; Bass, Barbara L. ; Collen, Martin J. ; Harmon, John W. ; Becker, Kenneth L. / Success of prolonged therapy with the somatostatin analog, octreotide acetate, in recalcitrant enterocutaneous fistulas. In: Digestive Surgery. 1989 ; Vol. 6, No. 3. pp. 142-145.
@article{302237c4410e42c697d5c1951c4cc7cf,
title = "Success of prolonged therapy with the somatostatin analog, octreotide acetate, in recalcitrant enterocutaneous fistulas",
abstract = "The somatostatin analog, octreotide acetate, has been reported to accelerate closure of enterocutaneous fistulas (ECF), and, if the closure does occur, it does so within 10 days of therapy. We report on the closure in 2 consecutive patients with recalcitrant, high output ECF after 4 and 6 weeks of octreotide acetate therapy. The changes in fistula output volume and content in response to the drug are described. Since long-term treatment with this drug is generally well tolerated and easy to administer, at least a 6-week course should be considered before resorting lo surgical resection.",
author = "Mark Tulchinsky and Bass, {Barbara L.} and Collen, {Martin J.} and Harmon, {John W.} and Becker, {Kenneth L.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1159/000171910",
language = "English (US)",
volume = "6",
pages = "142--145",
journal = "Digestive Surgery",
issn = "0253-4886",
publisher = "S. Karger AG",
number = "3",

}

Success of prolonged therapy with the somatostatin analog, octreotide acetate, in recalcitrant enterocutaneous fistulas. / Tulchinsky, Mark; Bass, Barbara L.; Collen, Martin J.; Harmon, John W.; Becker, Kenneth L.

In: Digestive Surgery, Vol. 6, No. 3, 01.01.1989, p. 142-145.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Success of prolonged therapy with the somatostatin analog, octreotide acetate, in recalcitrant enterocutaneous fistulas

AU - Tulchinsky, Mark

AU - Bass, Barbara L.

AU - Collen, Martin J.

AU - Harmon, John W.

AU - Becker, Kenneth L.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - The somatostatin analog, octreotide acetate, has been reported to accelerate closure of enterocutaneous fistulas (ECF), and, if the closure does occur, it does so within 10 days of therapy. We report on the closure in 2 consecutive patients with recalcitrant, high output ECF after 4 and 6 weeks of octreotide acetate therapy. The changes in fistula output volume and content in response to the drug are described. Since long-term treatment with this drug is generally well tolerated and easy to administer, at least a 6-week course should be considered before resorting lo surgical resection.

AB - The somatostatin analog, octreotide acetate, has been reported to accelerate closure of enterocutaneous fistulas (ECF), and, if the closure does occur, it does so within 10 days of therapy. We report on the closure in 2 consecutive patients with recalcitrant, high output ECF after 4 and 6 weeks of octreotide acetate therapy. The changes in fistula output volume and content in response to the drug are described. Since long-term treatment with this drug is generally well tolerated and easy to administer, at least a 6-week course should be considered before resorting lo surgical resection.

UR - http://www.scopus.com/inward/record.url?scp=0024785691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024785691&partnerID=8YFLogxK

U2 - 10.1159/000171910

DO - 10.1159/000171910

M3 - Article

AN - SCOPUS:0024785691

VL - 6

SP - 142

EP - 145

JO - Digestive Surgery

JF - Digestive Surgery

SN - 0253-4886

IS - 3

ER -